Pfizer’s New Executive Committee Streamlines Upper Management
This article was originally published in The Pink Sheet Daily
Executive Summary
Global Pharmaceuticals President Katen, General Counsel Kindler and CFO Shedlarz will become vice chairmen. Katen will now have oversight of the company’s R&D, manufacturing and licensing activities. Shedlarz will lose CFO title but pick up responsibility for human resources.
You may also be interested in...
Pfizer Restructuring Expands Shedlarz' Responsibilities As Katen Departs
New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.